Novartis Clinical Trial Pipeline — 367 Active Studies

Phases, active trials: Phase 1: 42, Phase 2: 96, Phase 3: 92, Other: 137

Novartis has a diversified late-stage pipeline spanning oncology, ophthalmology, cardiovascular, and immunology. Their radioligand therapy (RLT) franchise — anchored by Lutathera and Pluvicto (lutetium PSMA-617) — has established Novartis as the leader in targeted radiotherapy for solid tumors. In breast cancer, Kisqali (ribociclib) continues expanding into new settings against CDK4/6 inhibitor competitors. Kymriah pioneered the CAR-T category, and Novartis continues investing in next-generation cell therapies. Their ophthalmology pipeline (Luxturna gene therapy, complement inhibitors for geographic atrophy) represents a major growth vector.

• Oncology (radioligand, CDK4/6, CAR-T)
• Ophthalmology / gene therapy
• Cardiovascular
• Immunology / inflammation
• Neuroscience

• Kisqali (ribociclib) — HR+ breast cancer CDK4/6 inhibitor
• Pluvicto (lutetium-177 PSMA) — metastatic prostate cancer
• Kymriah (tisagenlecleucel) — CAR-T lymphoma/leukemia
• Cosentyx (secukinumab) — IL-17A, psoriasis/ankylosing spondylitis
• Iptacopan — complement Factor B, IgA nephropathy
• Scemblix (asciminib) — BCR-ABL1 CML

Novartis regularly initiates combination trials for Kisqali and Pluvicto in new patient populations. Their radioligand therapy pipeline expansion — beyond PSMA into SSTR2 and other targets — is one of the most watched programs in oncology BD.

DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Novartis's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.

• Sponsor normalization: Novartis may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
• Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
• Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
• Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
• Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.